hGH fragment raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-01-31 and is reviewed periodically as new material appears.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
Recipe Unlimited (previously known as Cara Operations) operates Harvey's, Swiss Chalet, Montana's Cookhouse, Kelsey's Neighbourhood Bar & Grill and other brands. The company also provides catering services to airlines. The revenue for its 1200 restaurants and its airline solutions division in 2008 was over $2 billion. Cara Airline Solutions operated about 10 flight kitchens across Canada that served more than 50 air carriers and rail travel customers, it was sold to Gategroup in 2010. Montana's Cookhouse started in 1995, was acquired by Cara in 2002, and operates 90 restaurants across Canada. There are 200 Swiss Chalet restaurants in Canada and the US. New York Fries is another Recipe Unlimited brand with about 200 stores in Canada, Hong Kong, UAE, Kuwait, and South Korea. New York Fries also had a burger company called South St. Burger, that sells burgers along with New York Fries and other products. It was spun off into a separate entity as part of the Cara acquisition. The largest Canadian-established hamburger chain in the nation, Harvey's was founded in Richmond Hill, Ontario, in 1959, it has franchises from Vancouver to St. John's, though most its restaurants are concentrated in southern Ontario and southern Quebec. On March 31, 2016, Cara announced that it would acquire the St-Hubert chain of rotisserie chicken restaurants in the summer of 2016. Recipe Unlimited also owns Prime Restaurants, the parent company of the restaurant chains East Side Mario's, Casey's, Pat and Mario's, Fionn MacCool's and Bier Markt Esplanade. Co-founded in Sudbury in 1980 by Bernard C.
=== Content === Drug-free hemp juice contains all of the ingredients of the hemp plant in their natural form and matrix. The highest content of cannabinoids and proteins can be found in the hemp plant prior to seed maturation when the hemp plant is still green. The main ingredients of hemp juice besides the presence omega-n-fatty acids are more than 100 cannabinoids, which are recognized by special receptors in the human body (endocannabinoid system and signal transduction). Hemp is the only botanical source of cannabinoids. Hemp juice contains many easily digestible proteins, in particular all of the eight essential amino acids important for humans. Furthermore, the juice contains a variety of minerals, vitamins and many polyphenols.
The main issues in the application of this technology are the lack of research into the flow control techniques, accuracy, and precision, the need for simpler operator procedures in the field, and the scaling of production to meet the volume requirements of a global market. This is largely due to the focus in the industry on utilizing the current silicon based manufacturing channels to commercialized LOC technologies more efficiently and economically.
The Department of Biochemistry, Cell and Systems Biology, sometimes abbreviated to BCSB, the department is a research-intensive centre of excellence at the University of Liverpool with significant international expertise in cellular proteomics, metabolomics, systems biology, cell signaling, bioinformatics and structural biology (including protein structure prediction and alphafold applications) that is based in refurbished laboratories and research facilities located in the Bioscience and Nuffield buildings of the Knowledge Centre/Quarter North Campus. With a continuous history of research-led discovery and teaching, BCSB contributes significantly to undergraduate and postgraduate teaching and training and is part of the Institute of Systems, Molecular and Integrative Biology, which was created in 2020 and represents a key research-intensive hub within the broader Faculty of Health and Life Sciences, holding > £300 million in its grant funding portfolios as of 2025. The 125th Anniversary of the founding of the department will be celebrated in 2027.
Ceramides are a family of waxy lipid molecules. A ceramide is composed of sphingosine and a fatty acid joined by an amide bond. Ceramides are found in high concentrations within the cell membrane of eukaryotic cells, since they are component lipids that make up sphingomyelin, one of the major lipids in the lipid bilayer. Contrary to previous assumptions that ceramides and other sphingolipids found in cell membrane were purely supporting structural elements, ceramide can participate in a variety of cellular signaling: examples include regulating differentiation, proliferation, and programmed cell death (PCD) of cells. The word ceramide comes from the Latin cera (wax) and amide. Ceramide is a component of vernix caseosa, the waxy or cheese-like white substance found coating the skin of newborn human infants.
Sources: en.wikipedia.org
=== Evacuation of Kabul === In August 2021, elements of the 82nd Airborne Division, particularly the Immediate Response Force, deployed to Afghanistan to secure the evacuation of American diplomats and Afghan Special Immigrant Visa applicants as the Taliban seized land and converged on Kabul. Throughout Operation Allies Refuge, the 82nd Airborne Division served as the Operational Command, Task Force 82. Operation Allies Refuge, led by Major General Chris Donahue, was a combined and joint NATO command post composed of forces representing NATO allied Nations, 1st Brigade Combat Team "Devil", aviation capabilities from the 82nd Combat Aviation Brigade "Pegasus", medical capabilities from the 44th Medical Brigade, riot control capabilities from the 16th Military Police Brigade, 24th Marine Expeditionary Unit, and the 3rd Expeditionary Sustainment Command who oversaw sustainment in the joint operational area from a command post in Kuwait.
== Components == Honey bee venom is a complex mixture of proteins and smaller molecules. The main component is melittin, which amounts to 52% of venom peptides. One of the main allergens is phospholipase A2, which amounts to 12% and is an enzyme that catalyzes the hydrolysis of phospholipids, causing degradation of cell membranes, causing cell death. Adolapin contributes 2–5% of the peptides. Further protein components include apamin (2%), a neurotoxin, hyaluronidase (2%), which dilates blood vessels, increasing their permeability and facilitating the spread of the venom, mast cell degranulating peptide (2%), tertiapin, and secapin. Small molecules in bee venom include histamine (0.1–1%), dopamine and noradrenaline.
Small humanin-like peptides (SHLPs) are a group of peptides encoded in the 16S ribosomal RNA region of mitochondrial genome. Six peptides of this group (SHLP1–6) have been identified so far, between 20-38 amino acids in length. They are derived from the mitochondria and act as important retrograde signaling molecules in the cell. Their names were given because the SHLPs share some similar biological effects with the mitochondrial peptide Humanin. Every individual SHLP showed unique expression pattern in mouse tissues. Specifically, SHLP1 was detected in the heart, kidney, and spleen; SHLP2 was detected in the liver, kidney, and muscle; SHLP3 was detected in the brain and spleen; SHLP4 was detected in the liver and prostate; and SHLP6 was detected in the liver and kidney. Experiments using cultured mammalian cells have shown that SHLPs are bioactive peptides. Incubation of each synthetic SHLP with cells affected cell viability, proliferation and apoptosis differentially, which suggests that every SHLP may play a different role in the biological system.
Christopher Cantelmo (June 19, 1962 – November 24, 2019) was an American biochemist. In 2019 he became known on Reddit under the username u/ChrisCGC for spending large sums on awards while promoting the use of DMT. The online activity around his posts was sometimes referred to as Cantelmoism.
== Medical uses == Both corticotropin and tetracosactide have been used for diagnostic purposes to determine adrenocortical insufficiency, particularly in Addison's disease, via the ACTH stimulation test. However, as of 2015 the US label for corticotropin does not include diagnostic use. Both corticotropin and tetracosactide have been used for therapeutic purposes. In the US the tetracosactide label is limited to diagnosis but the UK label provides for therapeutic uses. In the US corticotropin is used to treat epileptic spasms in infants, acute exacerbations of multiple sclerosis in adults; acute episodes of psoriatic arthritis and rheumatoid arthritis and ankylosing spondylitis; in acute exacerbations or as maintenance therapy for collagen disorders like systemic lupus erythematosus and systemic dermatomyositis; for skin conditions like severe erythema multiforme and Stevens–Johnson syndrome; for serum sickness; for severe acute and chronic allergic and inflammatory processes involving the eye such as keratitis, iritis and iridocyclitis, diffuse posterior uveitis, choroiditis, optic neuritis, chorioretinitis, and anterior segment inflammation; sarcoidosis in the lungs; and to treat edema in certain nephrotic syndromes. In the UK tetracosactide is used for short-term therapy in conditions for which glucocorticoids are usually used but for some reason should not be; some uses include use for people who do not respond to glucocorticoids or cannot tolerate them who have ulcerative colitis, Crohn's disease, juvenile rheumatoid arthritis, rheumatoid arthritis, or osteoarthrosis.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.